Neuphoria Therapeutics (NEUP) Common Equity (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Common Equity of $29.4 million for Q1 2026, up 13.18% year-over-year from $26.0 million in Q1 2025, and down 0.93% quarter-over-quarter from $29.7 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Common Equity (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Common Equity for 7 consecutive years, with $29.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 13.18% year-over-year to $29.4 million; the TTM figure through Mar 2026 stood at $29.4 million (up 13.18% YoY), while the FY2025 annual figure was $19.0 million, up 8.65% from the prior year.
- Common Equity fell to $29.4 million in Q1 2026 per NEUP's latest filing, from $29.7 million in the prior quarter.
- Across five years, Common Equity topped out at $40.8 million in Q2 2022 and bottomed at $12.5 million in Q3 2025.
- Historically, Common Equity has averaged $21.7 million across 5 years, with a median of $19.0 million in 2025.
- Annual changes were most pronounced in 2023 — Common Equity slumped 45.65% — and 2025, when it soared 116.04%.
- Neuphoria Therapeutics' Common Equity stood at $40.8 million in 2022, then slumped by 52.17% to $19.5 million in 2023, then retreated by 29.49% to $13.7 million in 2024, then jumped by 116.04% to $29.7 million in 2025, then decreased by 0.93% to $29.4 million in 2026.
- Business Quant data shows NEUP's Common Equity at $29.4 million in Q1 2026, $29.7 million in Q4 2025, and $12.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 29.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.42 Mn |
| Dec 31, 2025 | 29.70 Mn |
| Sep 30, 2025 | 12.51 Mn |
| Jun 30, 2025 | 19.00 Mn |
| Mar 31, 2025 | 26.00 Mn |
| Dec 31, 2024 | 13.75 Mn |
| Sep 30, 2024 | 17.07 Mn |
| Jun 30, 2024 | 17.49 Mn |
| Mar 31, 2024 | 17.95 Mn |
| Dec 31, 2023 | 19.50 Mn |
| Sep 30, 2023 | 17.23 Mn |
| Jun 30, 2023 | 22.15 Mn |
| Jun 30, 2022 | 40.76 Mn |
| Jun 30, 2021 | 36.65 Mn |
| Jun 30, 2020 | 8.31 Mn |